Health Economics of Use Fluoroquinolones to Treat Patients with Community-Acquired Pneumonia

Marcos I. Restrepo, Christopher R. Frei

Resultado de la investigación: Articlerevisión exhaustiva

8 Citas (Scopus)

Resumen

Respiratory diseases account for approximately 10% of all hospital admissions in the United States. Pneumonia constitutes 35% of these cases, with an average length of stay (LOS) of 5.1 days. It is estimated that $8.4 billion to $10 billion of all annual US hospital expenditures are attributable to community-acquired pneumonia (CAP). As such, medical decisions, including empiric antibiotic choice, potentially exert an impact on hospital LOS and associated costs. In this review, we focus on the empiric antibiotic choices and associated costs of treatment for hospitalized patients with CAP, focusing on the use of fluoroquinolone therapy as recommended by the CAP guidelines.

Idioma originalEnglish (US)
Páginas (desde-hasta)S39-S46
PublicaciónAmerican Journal of Medicine
Volumen123
N.º4 SUPPL.
DOI
EstadoPublished - abr. 2010

ASJC Scopus subject areas

  • Medicine(all)

Huella

Profundice en los temas de investigación de 'Health Economics of Use Fluoroquinolones to Treat Patients with Community-Acquired Pneumonia'. En conjunto forman una huella única.

Citar esto